164 related articles for article (PubMed ID: 10818458)
1. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry.
Yoon HR; Kim H; Cho SH
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):85-92. PubMed ID: 12668074
[TBL] [Abstract][Full Text] [Related]
3. Lysophospholipids are potential biomarkers of ovarian cancer.
Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
5. Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine.
Zhao Z; Xu Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3739-42. PubMed ID: 19734112
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of lysophosphatidic acid by LC/ESI/MS/MS employing a reversed phase HPLC column.
Shan L; Jaffe K; Li S; Davis L
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):22-8. PubMed ID: 18262478
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
Lu Z; Chen Y; Hu Z; Hu C
Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
[TBL] [Abstract][Full Text] [Related]
9. [Lysophosphatidic acid in ovarian cancer patients].
Sedlákova I; Vávrová J; Tosner J; Hanousek L
Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
[TBL] [Abstract][Full Text] [Related]
10. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
[TBL] [Abstract][Full Text] [Related]
11. Quantification of lysophosphatidic acids in rat brain tissue by liquid chromatography-electrospray tandem mass spectrometry.
Aaltonen N; Laitinen JT; Lehtonen M
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(15-16):1145-52. PubMed ID: 20381434
[TBL] [Abstract][Full Text] [Related]
12. Methods for quantifying lysophosphatidic acid in body fluids: a review.
Jesionowska A; Cecerska E; Dolegowska B
Anal Biochem; 2014 May; 453():38-43. PubMed ID: 24613261
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a specific and sensitive HPLC-ESI-MS method for quantification of lysophosphatidylinositols and evaluation of their levels in mice tissues.
Masquelier J; Muccioli GG
J Pharm Biomed Anal; 2016 Jul; 126():132-40. PubMed ID: 27208623
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic acid: an ovarian cancer marker.
Sedláková I; Vávrová J; Tosner J; Hanousek L
Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
[TBL] [Abstract][Full Text] [Related]
16. Altered plasma levels of lysophospholipids in response to adrenalectomy of rats.
Tsutsumi T; Ino M; Shimizu Y; Kawabata K; Nishi H; Tokumura A
Prostaglandins Other Lipid Mediat; 2021 Oct; 156():106579. PubMed ID: 34245896
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous profiling of lysophospholipids and phospholipids from human plasma by nanoflow liquid chromatography-tandem mass spectrometry.
Lee JY; Min HK; Moon MH
Anal Bioanal Chem; 2011 Jul; 400(9):2953-61. PubMed ID: 21499968
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
Sedláková I; Vávrová J; Tošner J; Hanousek L
Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
[TBL] [Abstract][Full Text] [Related]
19. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
[TBL] [Abstract][Full Text] [Related]
20. Serum Lysophosphatidic Acid Measurement by Liquid Chromatography-Mass Spectrometry in COPD Patients.
Li Q; Wong WR; Chakrabarti A; Birnberg A; Yang X; Verschueren E; Neighbors M; Rosenberger C; Grimbaldeston M; Tew GW; Sandoval W
J Am Soc Mass Spectrom; 2021 Aug; 32(8):1987-1997. PubMed ID: 33754705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
